Asian Fund for Cancer Research Limited shared on LinkedIn:
“Pancreatic cancer is one of the most lethal malignancies, with only about 15–20% of patients eligible for surgical resection.
At the AFCR–CityU Symposium on Precision and Digital Medicine at BIOHK2024, Asian Fund for Cancer Research Limited (AFCR) Scientific Advisory Board member Professor Min Li of the University of Oklahoma shared his team’s research on the zinc transporter ZIP4 in pancreatic cancer and cancer cachexia.
The research showed that ZIP4 is significantly overexpressed in pancreatic cancer and is associated with tumor growth, metastasis, and chemotherapy resistance.
His team also linked ZIP4 to the muscle wasting seen in cancer cachexia.
In multiple mouse models, targeting ZIP4 suppressed tumor progression, helped preserve muscle mass, and improved survival, highlighting its potential as a diagnostic biomarker and therapeutic target.
We look forward to connecting with experts and innovators across disciplines at the upcoming BIOHK2026 and exploring new opportunities to advance cancer research, precision medicine, and healthcare innovation.”
Other articles about Asian Fund for Cancer Research Limited on OncoDaily.